These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 1300737)

  • 21. Clinical evaluation of new serum tumor markers CA M26 and CA M29 in patients with primary breast cancer.
    Eskelinen M; Tikanoja S; Brown J
    Anticancer Res; 1990; 10(4):959-62. PubMed ID: 2382995
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of mucinous-like cancer antigen (MCA) in women with breast disease: preliminary results.
    Valenti G; Zanardi S; Valtolina M; Bombardieri E; Boccardo F
    Cancer Detect Prev; 1991; 15(4):285-9. PubMed ID: 1794135
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical value of a new tumor marker (M.C.A.) in the breast cancer follow-up.
    Cappellari A; Bagarella M; Corradi G
    Boll Ist Sieroter Milan; 1990; 69(1):315-8. PubMed ID: 2102115
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Is follow-up of breast cancer with CEA and CA 15-3 justified?].
    Fritsche E; Benz J
    Helv Chir Acta; 1992 May; 59(1):225-9. PubMed ID: 1526832
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An evaluation of CA 549, a circulating marker of breast cancer using a procedure for comparison with CA 15.3.
    Cazin JL; Gosselin P; Boniface B; Demaille MC; Demaille A
    Anticancer Res; 1992; 12(3):719-24. PubMed ID: 1622129
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CEA, TPS, CA 19-9 and CA 72-4 and the fecal occult blood test in the preoperative diagnosis and follow-up after resective surgery of colorectal cancer.
    Griesenberg D; Nürnberg R; Bahlo M; Klapdor R
    Anticancer Res; 1999; 19(4A):2443-50. PubMed ID: 10470173
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The serum tumor marker M3/M21 in the follow-up of breast cancer patients.
    Tempfer C; Hanzal E; Zeillinger R; Koelbl H; Dadak C; Kainz C
    Anticancer Res; 1996; 16(5B):3049-52. PubMed ID: 8920765
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Small intestinal mucin antigen (SIMA); a novel tumour marker in colorectal cancer?
    Eskelinen M; Pasanen P; Janatuinen E; Pettersson N; Linnane A; Alhava E
    Anticancer Res; 1995; 15(5B):2351-6. PubMed ID: 8572651
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mammary serum antigen (MSA), Ca 549, CA 15-3 and CEA in breast cancer preoperative sensitivity and correlation to prognostic factors.
    Heinze T; Schürenkämper P; Minguillon C; Lichtenegger W
    Anticancer Res; 1997; 17(4B):2953-4. PubMed ID: 9329573
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of MCA and CA 15-3 in tissue and in serum of patients with breast carcinoma: preliminary results.
    Reale G; Giovagnoli MR; Vecchione A; Cosentino L; Benci F; Manna A; Marchei G; Vittori I; Frati L
    J Nucl Med Allied Sci; 1990; 34(4 Suppl):53. PubMed ID: 2092150
    [No Abstract]   [Full Text] [Related]  

  • 31. Clinical evaluation of the Elecsys CA 15-3 test in breast cancer patients.
    Stieber P; Molina R; Chan DW; Fritsche HA; Beyrau R; Bonfrer JM; Filella X; Gornet TG; Hoff T; Jäger W; van Kamp GJ; Nagel D; Peisker K; Sokoll LJ; Troalen F; Untch M; Domke I
    Clin Lab; 2003; 49(1-2):15-24. PubMed ID: 12593471
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumor associated glycoprotein (TAG) 12: a new tumor marker in breast cancer.
    Heinze T; Lichtenegger W
    Anticancer Res; 2000; 20(6D):5049-52. PubMed ID: 11326666
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A comparative study of mucin-like carcinoma-associated antigen (MCA), CA 125, CA 19-9 and CEA in patients with ovarian cancer.
    Koelbl H; Schieder K; Neunteufel W; Bieglmayer C
    Neoplasma; 1989; 36(4):473-8. PubMed ID: 2770933
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early diagnosis of breast cancer dissemination by tumor markers follow-up and method of prediction.
    Nekulová M; Simícková M; Pecen L; Eben K; Vermousek I; Stratil P; Cernoch M; Lang B
    Neoplasma; 1994; 41(2):113-8. PubMed ID: 8208314
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [CA 15-3 associated with CEA and TPA in the follow-up of breast carcinoma].
    Maffei S; Rudoni M; Antonini G; Sacchetti G; Krengli M
    Minerva Med; 1990 Nov; 81(11):759-63. PubMed ID: 2255409
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of serum CA549, CA M26 and CA M29 levels in the post-operative follow-up of breast cancer patients.
    Nicolini A; Ferdeghini M; Colombini C; Carpi A
    J Nucl Med Allied Sci; 1990; 34(4):309-13. PubMed ID: 2090796
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Determination of serum tumor markers TPS and CA 15-3 during monitoring of treatment in metastatic breast cancer patients.
    Schuurman JJ; Bong SB; Einarsson R
    Anticancer Res; 1996; 16(4B):2169-72. PubMed ID: 8694538
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Potential use of tumour marker CA 15-3 in the staging and prognosis of patients with breast cancer.
    Horobin JM; Browning MC; McFarlane NP; Smith G; Preece PE; Wood RA; Cuschieri A
    J R Coll Surg Edinb; 1991 Aug; 36(4):219-21. PubMed ID: 1941734
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Predictive value of the tumor marker combination CA-125 and beta-2-microglobulin in ovarian cancer].
    Hernádi Z; Molnár V; Juhász B; Pólka R; Margitai B
    Zentralbl Gynakol; 1992; 114(1):6-9. PubMed ID: 1585745
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Tumor markers in the early diagnosis of recurrence in gynecologic neoplasms: combined determination of CA-125, CA 15-3, CA 72.4, SCC, 90 K].
    Garzetti GC; Di Lauro RM; Ciavattini A; Pallotta MR; Marchegiani F; Valensise H; Tranquilli AL; Arduini D; Romanini C
    Ann Ostet Ginecol Med Perinat; 1991; 112(5):320-3. PubMed ID: 1817444
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.